研究单位：[1]Sichuan Cancer Hospital and Research Institute[2]West China Hospital,Sichuan University Chengdu,Sichuan,China,610041[3]Sichuan Provincial People's Hospital Chengdu,Sichuan,China,610071[4]Jiangsu HengRui Medicine Co.,Ltd.
研究目的：
This phase 2 study is designed to evaluate the safety and activity of apatinib,a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2,in combination with EGFR-TKI in NSCLC with T790M-negative after the failure of EGFR-TKI therapy.
